This is the latest paper from Dr Agrawal and Professor Borody on AMAT in paediatric Crohn’s disease. “The study provides a valuable and novel proof of concept regarding the applicability of AMAT to a broad range of clinical presentations in paediatric Crohn’s disease patients. We report no significant side effects as a result of a dose escalated, sustained antibiotic regimen andsuggest that AMAT may be more efficacious in the treatment of childhood onset compared with adult onset CD.”
Dr Gaurav Agrawal and microbiologist John Aitken talk with Dr Samir Kakodkar about Crohn’s disease and MAP. We have linked to the part where the Crohn’s MAP Vaccine is mentioned, as it is a very long podcast. However, if you have the time, please listen to the whole video as it answers so many questions that people ask us. Enjoy!
On 19th May it’s World IBD Day. The talented Julie McCombe of www.mccoydesign.com.au has created a beautiful purple rainbow for us which we can share far and wide on social media to raise awareness of the many shades of IBD.
And (as if that weren’t enough!) she has also created a blank for colouring in and displaying in windows or around the workplace. So get out your mauves, indigos, lilacs, purples and violets, download and start colouring!
Enjoy!
instagram.com/crohnsmapvaccine
twitter.com/crohnsvaccine
facebook.com/crohnsmapvaccine
#crohns #crohnsdisease #IBD #vaccine #Crohnsvaccine www.crohnsmapvaccine.com
I wanted to bring you an update and send my best wishes in these unprecedented times. I expect it may have been a very difficult Easter for many of you, being unable to spend time with family and friends and struggling with all the hardships and uncertainties this pandemic has brought. My thoughts are with all those who are sick and those who have lost loved ones. A heartfelt thanks goes to all my former colleagues in the NHS and to key workers who are working to save lives and keep our country going. Myself and my wife are self-isolating at home, in accordance with the government guidelines. We are very lucky to have a garden in which to enjoy the beautiful Spring sunshine. Please stay home too, stay safe and don’t lose hope!
As with so
many things, covid-19 is having a major impact on research. At the point
at which the pandemic struck, our Phase II vaccine trial was set up and
awaiting the final local authorisations to begin. However, all clinical
research not directly related to coronavirus has now been paused. This
is because taking part in a trial would put patients at risk of catching
covid-19, due to the travel involved as well as the inability to
maintain social distancing during appointments. Similarly, all
laboratory research not related to coronavirus is also on hold (due to
the risk of spreading the virus with staff travelling to and from work)
and King’s College London is closed. Hence work on our MAP test is
currently paused too. We will be ready to go as soon as social
distancing requirements are relaxed and permission is given for
non-covid related clinical trials to restart and labs to re-open.
I would like to thank all our wonderful supporters for your continuing support during this very difficult time.
Another paper from Borody et al on the use of antibiotic therapy and Faecal Microbiota Transplantation (FMT).
Prolonged remission has been achieved for 3–23 years with individualised treatments, with the majority using AMAT ± infliximab and FMT. Treatment with antibiotics and/or FMT provides a potential new avenue for treatment of CD. These findings should stimulate thinking, investigations and better therapy against MAP and the dysbiosis of the gut flora, to enable higher rates of prolonged remission.
In this recent paper from Professor Thomas Borody and Doctor G Agrawal, AMAT as first-line therapy demonstrated a rapid improvement of Crohn’s disease not previously seen when used as second-line therapy.
This is an excellent explanation of the results from Redhill Biopharma’s trial of RHB-104, a formulation of three antibiotics against MAP to treat Crohn’s disease. All research in this area is very welcome as we head into phase 2 trial of the Crohn’s MAP Vaccine.
President and Principal of King’s College London, Professor Edward Byrne, thanks everyone who has supported Crohn’s test research. In the booklet you can also read contributions from Professor Hermon-Taylor, Dr Amy Hermon-Taylor, Dr Gaurav Agrawal, Dr Paul Cross, Research Fellow Neil Rayment and fundraiser Christine Clifford.
KCL FSD THANK YOU BROCHURE – CROHNS 2019 – DIGITAL AW